ALKERMES | ALKS - Equity Capital And Reserves


ALKERMES reported $1.73B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
ALKERMES USD 1.73B 108.85M Sep/2025
Amgen USD 8.66B 961M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Coherus Biosciences USD 87.77M 32.05M Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 78.47B 0 Sep/2025
Malin Corporation EUR 193.2M 75M Dec/2024
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Otsuka Holdings JPY 3.03T 174.32B Dec/2025
Ovoca Bio EUR 8.67M 4.76M Jun/2022
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025